Lumos Pharma, Inc. Common Stock
LUMO
LUMO was delisted on the 11th of December, 2024.
152 hedge funds and large institutions have $567M invested in Lumos Pharma, Inc. Common Stock in 2015 Q3 according to their latest regulatory filings, with 23 funds opening new positions, 45 increasing their positions, 55 reducing their positions, and 15 closing their positions.
137% more call options, than puts
Call options by funds: $50.6M | Put options by funds: $21.3M
53% more first-time investments, than exits
New positions opened: 23 | Existing positions closed: 15
5% more funds holding
Funds holding: 145 → 152 (+7)
18% less repeat investments, than reductions
Existing positions increased: 45 | Existing positions reduced: 55
19% less capital invested
Capital invested by funds: $700M → $567M (-$133M)
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
O
OrbiMed
New York
|
+$34.8M |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$8.85M |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$8.27M |
| 4 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
+$8.24M |
| 5 |
Renaissance Technologies
New York
|
+$7.72M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
GAM
Gotham Asset Management
New York
|
-$55.1M |
| 2 |
Millennium Management
New York
|
-$12.6M |
| 3 |
AP
AHL Partners
London,
United Kingdom
|
-$4.68M |
| 4 |
WSA
Wall Street Associates
Lajolla,
California
|
-$4.35M |
| 5 |
CNB
City National Bank
Beverly Hills,
California
|
-$3.88M |
LUMO Hedge Fund Activity: Q3 2015 in Review
152 of the 3,582 institutional investors tracked by Wall St. Rank reported a position in Lumos Pharma, Inc. Common Stock (LUMO) for Q3 2015, worth a combined $567M — down 19% from $700M a quarter earlier.
Buyers outnumbered sellers: 23 funds opened new LUMO positions and 15 closed out — a net gain of 8 holders — while 45 added to existing stakes and 55 trimmed.
The largest buyer was OrbiMed, opening a new position worth an estimated $34.8M. The largest seller was Gotham Asset Management, exiting entirely with an estimated $55.1M sold.
- 152 institutional investors held Lumos Pharma, Inc. Common Stock (LUMO) as of Q3 2015, up from 145 in Q2 2015.
- Funds reported $567M of Lumos Pharma, Inc. Common Stock stock for Q3 2015, down 19% quarter-over-quarter.
- 23 funds opened new Lumos Pharma, Inc. Common Stock positions in Q3 2015 and 15 closed out, a net change of +8 holders.
- The largest Lumos Pharma, Inc. Common Stock buyer in Q3 2015 was OrbiMed, an estimated $34.8M added.
- The largest Lumos Pharma, Inc. Common Stock seller in Q3 2015 was Gotham Asset Management, an estimated $55.1M sold.
Based on aggregated 13F filings for Q3 2015.